巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    HUTCHMED (China) Limited

    HCM
    8.250
    1.390
    14.42%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・HUTCHMED (China) Limited - 延遲價格・最後更新於 24/05 8:29
    最高位
    9.270
    最低位
    8.250
    開市價
    --
    前收市價
    9.640
    成交量(千)
    54.26
    成交額(百萬)
    4.36
    買入
    8.100
    賣出
    --
    每手股數
    --
    市值(百萬)
    1,426.48
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    43.940 - 8.580
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    HUTCHMED (China) Limited
    證券代碼
    HCM.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
    發行量
    172906170
    公司總部
    2 Queen's Road Central, 48th Floor, Cheung Kong Center
    公司網址
    https://www.hutch-med.com
    公司電郵
    ir@chi-med.com
    公司電話
    +852 21218200

    美股異動 | 和黃醫藥跌5% 用於治療胰腺和非胰腺神經內分泌瘤新藥上市遭拒

    格隆匯·
    美股異動 | 和黃醫藥跌5% 用於治療胰腺和非胰腺神經內分泌瘤新藥上市遭拒

    美股異動 | 和黃醫藥跌5% 用於治療胰腺和非胰腺神經內分泌瘤新藥上市遭拒

    格隆匯·
    美股異動 | 和黃醫藥跌5% 用於治療胰腺和非胰腺神經內分泌瘤新藥上市遭拒

    和黃醫藥(00013.HK)獲The Capital Group增持279.08萬股

    格隆匯·
    和黃醫藥(00013.HK)獲The Capital Group增持279.08萬股

    熱門中概股集體走低

    格隆匯·
    熱門中概股集體走低

    熱門中概股集體走低

    格隆匯··精選
    熱門中概股集體走低

    關於

    HUTCHMED (China) Limited(HCM.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
    詳細公司背景可參考: https://www.hutch-med.com